Abstract
The incidence of cytomegalovirus (CMV) reactivation/disease after autologous stem cell transplant (ASCT) is much lower than that after allogeneic stem cell transplantation. With the recent use of rituximab during cancer chemotherapy or conditioning regimens prior to transplantation, there has been an increasing concern of opportunistic infections including CMV. In the present study, we reviewed the patients undergoing ASCT from December 2007 to December 2013 to identify those developing CMV reactivation/disease. Out of the 978 patients who underwent ASCT at the Karmanos Cancer Institute, 239 patients were tested for symptomatic CMV reactivation based on clinical suspicion. Of the tested patients, 7/239 (2.9 %) were documented to have CMV reactivation within 90 days of ASCT. The median time to develop CMV viremia was 32 days from transplantation. Of the 239 patients tested, CMV viremia was detected in 3 out of 72 patients who received rituximab as compared to 4 out of 167 patients who did not. Three of these seven viremic patients were treated with anti-viral drugs; viremia resolved in all patients at a median of 24 days. Three patients were found to develop other bacterial and/or fungal infections following CMV viremia. Two of the seven patients died during 1-year follow-up, due to primary disease progression or Candida sepsis. None of the patients developed proven tissue-invasive CMV disease. The study did not evaluate the incidence of asymptomatic CMV infection/reactivation. Despite prior publications based on limited data, rituximab does not appear to contribute to an increased frequency of symptomatic CMV reactivation following ASCT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fassas AB, Bolanos-Meade J, Buddharaju LN et al (2001) Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 112:237–241
Boeckh M, Stevens-Ayers T, Bowden RA (1996) Cytomegalovirus pp 65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 174:907–912
Konoplev S, Champlin RE, Giralt S et al (2001) Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 27:877–881
Bilgrami S, Aslanzadeh J, Feingold JM et al (1999) Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bone Marrow Transplant 24:69–73
Holmberg LA, Boeckh M, Hooper H et al (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029–4035
Rossini F, Terruzzi E, Cammarota S et al (2005) Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis Off J Transplant Soc 7:122–125
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
Fenske TS, Hari PN, Carreras J et al (2009) Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15:1455–1464
Goldberg SL, Pecora AL, Alter RS et al (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486–1488
Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000
Lee MY, Chiou TJ, Hsiao LT et al (2008) Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 87:285–289
Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 15:e2–e16
Al-Rawi O, Abdel-Rahman F, Al-Najjar R et al (2015) Cytomegalovirus reactivation in adult recipients of autologous stem cell transplantation: a single center experience. Mediterr J Hematol Infect Dis 7:e2015049
Marchesi F, Mengarelli A, Giannotti F et al (2014) High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network. Transpl Infect Dis Off J Transplant Soc 16:158–164
Kim JH, Goulston C, Sanders S et al (2012) Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18:1753–1758
Marchesi F, Pimpinelli F, Dessanti ML et al (2014) Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study. Transpl Infect Dis Off J Transplant Soc 16:1032–1038
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval
The study was approved by the Institutional Review Board at Wayne State University and Karmanos Cancer Center, Detroit, MI.
Rights and permissions
About this article
Cite this article
Jain, T., John, J., Kotecha, A. et al. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. Ann Hematol 95, 1323–1327 (2016). https://doi.org/10.1007/s00277-016-2700-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2700-4